Kim Kjøller, Union Therapeutics CEO

In­novent bets $250M+ on Union's PDE4 in­hibitor ahead of a PhII read­out

A year af­ter pluck­ing oris­mi­last from Leo Phar­ma­ceu­ti­cals’ pipeline — and with­out pub­lish­ing any mid-stage da­ta — Union Ther­a­peu­tics is al­ready mak­ing a pret­ty pen­ny on the oral PDE4 in­hibitor.

In­novent Bi­o­log­ics is shelling out $20 mil­lion up­front for de­vel­op­ment and com­mer­cial­iza­tion rights to Union’s “Phase III-ready” oral for­mu­la­tion of oris­mi­last in Chi­na, the com­pa­nies said ear­ly Tues­day morn­ing. Hop­ing to one-up Am­gen’s block­buster PDE4 in­hibitor Ote­zla in terms of po­ten­cy, Union’s been push­ing the can­di­date through Phase II tri­als in skin con­di­tions like pso­ri­a­sis, atopic der­mati­tis and hidradeni­tis sup­pu­ra­ti­va.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.